Molecular dynamics and artificial intelligence based tools to innovate covalent and noncovalent drug design
Ended Project Grant Awarded Last action
- Award ID
- R44GM134756
- Recipient
-
Computchem, LLC UEI TJV7T8A8Y2X1
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,450,786
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Originally
- Funding
-
- $2,747,994.00 Federal
- $702,792.00 Non-federal
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cancer and infectious diseases are threatening modern human kind. To combat the challenge, targeted cova- lent inhibition and targeted protein degradation are emerging as the new frontiers in drug discovery. This sbir project seeks to meet two unmet needs in the emerging covalent as well as traditional reversible drug discovery programs by developing two commercial solutions based on cutting-edge research in molecular simulations and data science. In the phase i period, computchem LLC has developed a local/cloud software application ititrate that can offer accurate and reliable predictions of protein PKA values and nucleophilic cysteine and lysine. As the RST of its kind, ititrate is based on a unique and extensively validated constant PH molecular dynamics approach and a very accurate and efcient generalized born implicit-solvent model. In phase i, computchem also devel- oped a prototype of a novel small-molecule PKA prediction tool based on articial intelligence. Building on the phase i progress, the objective of the phase II project is to signicantly accelerate, enhance, and demonstrate the capabilities of ititrate and improve the accuracy of IKA. Ititrate can be applied to expedite efforts in a vari- ETY of covalent drug discovery programs, including targeted covalent inhibitor design; kinome or proteome wide scanning for covalently targetable sites; protein-protein interaction inhibition; and proteolysis targeting chimera design. Ititrate can be further developed and integrated with IKA to offer a novel solution for accurate protonation state assignment and PH-dependent modeling of protein-ligand complexes, which would add signicant value to computer-aided lead optimization and other in silico drug design tasks.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $671,205 | $0 | |
| Amendment | $671,205 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $702,792 | $0 | |
| Original award | $702,792 | $702,792 |
Show all 11
Quick answers
Who received award R44GM134756?
R44GM134756 was awarded to Computchem, LLC by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2019.
How much is award R44GM134756 worth?
$3,450,786 has been obligated on R44GM134756: $2,747,994 in federal funding and $702,792 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award